Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sertraline TQT Study
NCT02651623Phase 1Completed
- Sponsor
- Viatris
- Start
- Jan 2016
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of sertraline in major depressive disorder (MDD) (3 arms), sponsored by Viatris. Primary endpoint: Postdose QTcF intervals. Started Jan 2016; status: completed.
02
Drugs
sertraline
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02651623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02651623.